Angle A CNS roll-up with 52% growth-product revenue and $125M synergy potential gives the rebound more than chart fuel.
Supernus is rebounding with a stronger structural story: Q2 revenue rose 32% YoY to $219.1M, growth products climbed 52% to $175.7M, and FY26 revenue guidance was raised [#8, #19]. The Indivior combination adds scale, 11 commercial products, $2.2B pro forma revenue, $888M pro forma adjusted EBITDA, and $125M annual synergy potential, making the bounce look like an early re-rate of a larger CNS platform rather than a pure oversold snapback [#12, #13, #24].
Catalyst The re-rating window is the next several weeks as investors digest the raised FY26 outlook and model the combined CNS platform's synergy and EBITDA profile.
HOLDAI Status:SUPN sits compressed at the lower Bollinger band with oversold stochastics and improving volume, while the downtrend keeps price below the EMA20 as the CNS platform story develops.
Bollinger %B at -0.02 with two recent closes at the lower band and bandwidth near 9.4% flags a stretched, mean-reversion-friendly spot even though EMA20 remains above price by about 4.4% in a weak-ADX downtrend. Stochastics %K near 4 with %D at 24 and daily RSI bullish divergence align with momentum and stochastics lanes favoring stabilization, while 1.22x average volume and rising OBV support accumulation rather than distribution. Weekly RSI near 35 and a still-negative MACD histogram keep the higher-timeframe repair incomplete, but the raised growth-product mix and Indivior scale narrative still fit a re-rating setup if price can reclaim short-term trend structure.
